At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,033 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study
In Brief
A Phase 3 clinical trial evaluating Placebo and Prasugrel for Acute Coronary Syndromes. Completed, enrolled 4,033 participants across 153 sites in 19 countries.
Detailed Summary
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndromes
CountriesAustria, Belgium, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, Sweden, Turkey (Türkiye)
CollaboratorsDaiichi Sankyo Co., Ltd.
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartDec 2009
Primary CompletionJan 2013
Study CompletionFeb 2013
TodayJul 2026
First PostedNov 18, 2009
Enrollment StartDec 1, 2009
Primary CompletionJan 1, 2013
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.6 years ago
Interventions
Placebodrug
Administered once orally
Prasugreldrug
Administered orally